Function, structure and therapeutic potential of complement C5a receptors.

Function, structure and therapeutic potential of complement C5a receptors. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Function, structure and therapeutic potential of complement C5a receptors. Abstract Text:

P N Monk,A-M Scola,P Madala,D P Fairlie,

Complement fragment (C)5a is a 74 residue pro-inflammatory polypeptide produced during activation of the complement cascade of serum proteins in response to foreign surfaces such as microorganisms and tissue damaged by physical or chemical injury. C5a binds to at least two seven-transmembrane domain receptors, C5aR (C5R1, CD88) and C5L2 (gpr77), expressed ubiquitously on a wide variety of cells but particularly on the surface of immune cells like macrophages, neutrophils and T cells. C5aR is a classical G protein-coupled receptor that signals through G alpha i and G alpha 16, whereas C5L2 does not appear to couple to G proteins and has no known signalling activity. Although C5a was first described as an anaphylatoxin and later as a leukocyte chemoattractant, the widespread expression of C5aR suggested more general functionality. Our understanding of the physiology of C5a has improved significantly in recent years through exploitation of receptor knockout and knocking mice, C5 and C5a antibodies, soluble recombinant C5a and C5a analogues and newly developed receptor antagonists. C5a is now also implicated in non-immunological functions associated with developmental biology, CNS development and neurodegeneration, tissue regeneration, and haematopoiesis. Combined receptor mutagenesis, molecular modelling, structure-activity relationship studies and species dependence for ligand potency on C5aR have been helpful for identifying ligand binding sites on the receptor and for defining mechanisms of receptor activation and inactivation. This review will highlight major developments in C5a receptor research that support C5aR as an important therapeutic target. The intriguing possibilities raised by the existence of a non-signalling C5a receptor are also discussed.

Function, structure and therapeutic potential of complement C5a receptors. Publishing Authors By Initials

PN Monk,AM Scola,P Madala,DP Fairlie,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Function, structure and therapeutic potential of complement C5a receptors. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: British journal of pharmacology

VOLUME: 152

Page Numbers: 429-48

Journal Abbreviation: Br. J. Pharmacol.

ISSN: 0007-1188

DAY: 2

MONTH: 07

YEAR: 2007

Function, structure and therapeutic potential of complement C5a receptors. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7502536

Function, structure and therapeutic potential of complement C5a receptors. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Function, structure and therapeutic potential of complement C5a receptors. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Function, structure and therapeutic potential of complement C5a receptors.

AFFILIATION: Academic Neurology Unit, School of Medicine and Biomedical Science, University of Sheffield, Sheffield, UK. p.monk@shef.ac.uk

Country: England

AGENCY: United Kingdom Wellcome T

GRANT: 072231

ACRONYM:

MEDLINETA: Br J Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Function, structure and therapeutic potential of complement C5a receptors Related Publications

• A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation.
• A refined agonist pharmacophore for protease activated receptor 2.
• Amyloid peptides and proteins in review.
• Cell phenotype as a target of drug therapy in chronic inflammatory diseases.
• Chronic gastritis as a source of gross hemorrhage; a report and discussion of four cases.
• Conformationally homogeneous cyclic tetrapeptides: useful new three-dimensional scaffolds.
• Consecutive cyclic pentapeptide modules form short alpha-helices that are very stable to water and denaturants.
• Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family.
• Current status of short synthetic peptides as vaccines.
• Cyclooligomerization of a helix-bearing template into macrocycles bearing multiple helices.
• EGL-1 BH3 mutants reveal the importance of protein levels and target affinity for cell-killing potency.
• Function, structure and therapeutic potential of complement C5a receptors.
• Hepta and octapeptide agonists of protease-activated receptor 2.
• Linkage Isomerism in the Binding of Pentapeptide Ac-His(Ala)3His-NH2 to (Ethylenediamine)Palladium(II): Effect of the Binding Mode on Peptide Conformation.
• New cysteine derivatives with antiproliferative activity on melanoma cells.
• New evidence of childhood leukaemias near nuclear power stations.
• Potent antimalarial activity of histone deacetylase inhibitor analogues.
• Profiling the enzymatic properties and inhibition of human complement factor B.
• Protease inhibitors in the clinic.
• Unexpected photolytic decomposition of alkyl azides under mild conditions.